Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer

British Journal of Cancer

Volumn 99, Issue 12, 2008, Pages 2054-2064

  Wilson, C ^a   Scullin, P ^a   Worthington, J ^b   Seaton, A ^a   Maxwell, P ^a   O'Rourke, D ^c   Johnston, P G ^a   McKeown, S R ^b   Wilson, R H ^a   O'Sullivan, J M ^a   Waugh, D J J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

^c BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Dexamethasone; Docetaxel; Prostate cancer

Indexed keywords

CXCL1 CHEMOKINE; DEXAMETHASONE; DOCETAXEL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; SYNAPSIN I; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CAPILLARY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SINGLE DRUG DOSE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; DEXAMETHASONE; ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-8; MALE; MICE; NF-KAPPA B; ORCHIECTOMY; PROSTATIC NEOPLASMS; TAXOIDS; TRANSCRIPTION FACTOR AP-1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 57449083765     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604804     Document Type: Article

References (40)

1. Abraham SM, Lawrence T, Kleiman A, Warden P, Medghalchi M, Tuckermann J, Saklatvala J, Clark AR (2006) Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase-1. J Exp Med 203: 1883-1889, doi:10.1084/jem.20060336
2. Akakura K, Suzuki H, Ueda T, Komiya A, Ichikawa T, Igarashi T, Ito H (2003) Possible mechanism of dexamethasone therapy for prostate cancer: suppression of circulating level of interleukin-6. Prostate 56: 106-109
3. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, Lokeshwar VB, Lokeshwar BL (2007) Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 67: 6854-6862, doi: 10.1158/0008-5472
4. Carollo M, Parente L, D'Alessandro N (1998) Dexamethasone-induced cytotoxic activity and drug resistance effects in androgen-independent prostate tumour PC3 cells are mediated by lipocortin 1. Oncol Res 10: 245-254
5. Caruso DJ, Carmack AJ, Lokeshwar VB, Duncan RC, Soloway MS, Lokeshwar BL (2008) Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. Clin Cancer Res 14: 4111-4118, doi: 10.1158/1078-0432
6. Collins TS, Lee LF, Ting JP (2000) Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-kappaB- and AP-1-dependent mechanism. Cancer Immunol Immunother 49: 78-84
7. De Bosscher K, Vanden Burghe W, Haegeman T (2003) The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 24: 488-522
8. Domingo-Domenech J, Mellado B, Ferrer B, Truan D, Codony-Servat J, Sauleda S, Alcover J, Campo E, Gascon P, Rovira A, Ross JS, Fernández PL, Albanell J (2005) Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer 93: 1285-1294, doi:10.1038/sj.bjc.6602851
9. Duan Z, Lamendola DE, Penson RT, Kronish KM, Seiden MV (2002) Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells. Cytokine 17: 234-242, doi:10.1006/cyto.2001.1008
10. Fradet V, Lessard L, Begin LR, Karakiewicz P, Masson AM, Saad F (2004) Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res 10: 8460-8464
11. Furst R, Schroeder T, Eilken HM, Bubik MF, Kiemer AK, Zahler S, Vollmar AM (2007) MAPK phosphatase-1 represents a novel anti-inflammatory target of glucocorticoids in the human endothelium. FASEB J 21: 74-80, doi: 10.1096/fj.06-6752com
12. Huang J, Yao JL, Zhang L, Bourne PA, Quinn AM, di Sant'Agnese PA, Reeder JA (2005) Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol 166: 1807-1815
13. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ (2001) Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20: 4188-4197
14. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP (2000) Interleukin 8 expression regulates tumourigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 6: 2104-2119
15. Issa R, Xie S, Khorasani N, Sukkar M, Adcock IM, Lee KY, Chung KF (2007) Corticosteroid inhibition of growth related oncogene protein alpha via mitogen-activated kinase phosphatase-1 in airway smooth muscle cells. J Immunol 178: 7366-7375
16. Kim SJ, Uehara H, Karashima T, McCarty M, Shih N, Fidler IJ (2001) Expression of interleukin-8 correlates with angiogenesis, tumourigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 3: 33-42
17. Maxwell PJ, Gallagher R, Seaton A, Wilson C, Scullin P, Pettigrew J, Stratford IJ, Williams KJ, Johnston PG, Waugh DJ (2007) HIF-1 and NF-kB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene 26: 7333- 7345, doi:10.1038/sj.onc.1210536
18. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, Southgate C, Easton DF, Eeles RA, Howell WM (2002) Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62: 3369-3372
19. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Sood AK (2008) Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 100: 359-372, doi:10.1093/jnci/ djn024
20. Murphy C, McGurk M, Pettigrew J, Santinelli A, Mazzucchelli R, Johnston PG, Montironi R, Waugh DJ (2005) Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res 11: 4117-4127
21. Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, Tokizane T, Fukui T, Ono Y, Inoue H, Shin M, Tsujimoto Y, Takayama H, Aozasa K, Okuyama A (2001) Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 93: 1739-1746
22. O'Rourke M, Ward C, Worthington J, McKenna J, Valentine A, Robson T, Hirst D, McKeown SR (2008) Evaluation of the antiangiogenic potential of AQ4N. Clin Cancer Res 14: 1502-1509, doi: 10.1158/1078-0432
23. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520
24. Ross JS, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP, Kaur P, Gray K, Stringer B (2004) Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin Cancer Res 10: 2466-2472
25. Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG, Waugh DJ (2008) Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis 29: 1148-1156, doi:10.1093/carcin/bgn109
26. Shukla S, MacLennan GT, Fu P, Patel J, Marengo SR, Resnick MI, Gupta S (2004) Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 6: 390-400
27. Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, Gardner T, Smith M, Nakshatri H, Cheng L (2004) Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 10: 5501-5507
28. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512
29. Uehara H, Troncoso P, Johnston D, Bucana CD, Dinney C, Dong Z, Fidler IJ, Pettaway CA (2005) Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate 64: 40-49
30. Uslu R, Sanli UA, Dikmen Y, Karabulut B, Ozsaran A, Sezgin C, Muezzinoglu GG, Omay SB, Goker E (2005) Predictive value of serum interleukin-8 levels in ovarian cancer patients treated with paclitaxel-containing regimens. Int J Gynecol Cancer 15: 240-245
31. Veltri RW, Miller MC, Zhao G, Ng A, Marley GM, Wright Jr GL, Vessella RL, Ralph D (1999) Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology 53: 139-147
32. Venkitaraman R, Thomas K, Huddart RA, Horwich A, Dearnaley DP, Parker CC (2008) Efficacy of low dose dexamethasone in castration-resistant prostate cancer. BJU Int 101: 440-443
33. Walters IA, Austin C, Austin R, Bonnert R, Cage P, Christie M, Ebden M, Gardiner S, Grahames C, Hill S, Hunt F, Jewell R, Lewis S, Martin I, Nicholls D, Robinson D (2008) Structure-activity relationships of a series of thiazolopyrimidine-based CXCR2 antagonists. Bioorg Med Chem Lett 18: 798-803
34. Waugh DJ, Wilson C, Seaton A, Maxwell PJ (2008) Multi-faceted roles for CXC-chemokines in prostate cancer progression. Front Biosci 13: 4595- 4604, doi.org/10.2741/3025
35. Wilson C, Wilson T, Johnston PG, Longley DB, Waugh DJ (2008a) Interleukin-8 signaling attenuates TRAIL and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther 7: 2649-2661, doi: 10.1158/1535-7163
36. Wilson C, Purcell C, Seaton A, Oladipo O, Maxwell PJ, O'Sullivan JM, Wilson RH, Johnston PG, Waugh DJJ (2008b) Chemotherapy-induced CXC-chemokine/CXCR2 signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of NF-κB transcription and evasion of apoptosis. J Pharmacol Exp Ther 327: 746-759
37. Wu W, Pew T, Zou M, Pang D, Conzen SD (2005) Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem 280: 4117-4124
38. Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K (2006) Glucocorticoids suppress tumour angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res 12: 3003-3009
39. Zhang C, Mattern J, Haferkamp A, Pfitzenmaier J, Hohenfellner M, Rittgen W, Edler L, Debatin KM, Groene E, Herr I (2006) Corticosteroid-induced chemotherapy resistance in urological cancers. Cancer Biol Ther 5: 59-64
40. Zhang C, Wenger T, Mattern J, Ilea S, Frey C, Gutwein P, Altevogt P, Bodenmüller W, Gassler N, Schnabel PA, Dienemann H, Marmé A, Hohenfellner M, Haferkamp A, Pfitzenmaier J, Gröne HJ, Kolb A, Büchler P, Büchler M, Friess H, Rittgen W, Edler L, Debatin KM, Krammer PH, Rutz HP, Herr I (2007) Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumours. Cancer Biol Ther 6: 278-287